J. Yao

发表

T. Buchholz, A. Kudelka, N. Thomakos, 1999, American journal of clinical oncology.

Significance of post-chemoradiation biopsy in predicting residual esophageal carcinoma in the surgical specimen.

J. Ajani, J. Roth, S. Swisher, 2004, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome.

J. Ajani, Tsung-Teh Wu, B. Feig, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial

R. Salazar, R. Riechelmann, E. Van Cutsem, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study

J. Hainsworth, E. Baudin, M. Pavel, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Activity & safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) origin, & gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who have progressed on prior treatment (Tx).

N. Raj, N. Fazio, P. Ruszniewski, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Meta-analysis of stomatitis in clinical studies of everolimus: incidence and relationship with efficacy

G. Hortobagyi, A. Ravaud, R. Motzer, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Association of VEGF expression with poor prognosis among patients with low-grade neuroendocrine carcinoma.

E. Abdalla, J. Abbruzzese, K. Xie, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

R. Salazar, R. Riechelmann, E. Van Cutsem, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Effect of everolimus treatment on chromogranin A, neuron-specific enolase, gastrin, and glucagon levels in patients with advanced pancreatic neuroendocrine tumors (pNET): Phase III RADIANT-3 study results.

E. D. de Vries, Z. Tsuchihashi, L. Sidéris, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Therapy of localized gastric cancer: preoperative and postoperative approaches.

J. Ajani, J. Yao, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical, pathological, and demographic factors associated with development of recurrences after surgical resection in elderly patients with neuroendocrine tumors

A. Dasari, Chan Shen, D. Halperin, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical, pathological, and demographic factors associated with development of recurrences after surgical resection in elderly patients with neuroendocrine tumors

A. Dasari, D. Halperin, J. Yao, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

A Phase I Dose Escalation Study of Apatinib Combinated with Docetaxel as Second-line Therapy for Advanced Gastric Carcinoma

H. Pan, Zhen Liu, J. Yao, 2021, Indian Journal of Pharmaceutical Sciences.

Everolimus plus octreotide LAR versus placebo plus octreotide LAR in patients with advanced neuroendocrine tumors (NET): Effect of prior somatostatin analog therapy on progression-free survival in the RADIANT-2 trial.

J. Hainsworth, E. Baudin, M. Pavel, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Everolimus in patients with advanced pancreatic neuroendocrine tumors (pNET): Impact of somatostatin analog use on progression-free survival in the RADIANT-3 trial.

E. Van Cutsem, T. Hobday, C. Lombard-Bohas, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Blockade of growth hormone receptor signaling by using pegvisomant: A functional therapeutic strategy in hepatocellular carcinoma

Manal M. Hassan, A. Rashid, R. Wolff, 2022, Frontiers in Oncology.

Phase I study of the safety and efficacy of atiprimod, a novel azaspirine, for patients with advanced cancer.

C. Ng, R. Kurzrock, L. Camacho, 2006, Journal of Clinical Oncology.

Phase II study of RAD001 (everolimus) and depot octreotide (Sandostatin LAR) in patients with advanced low grade neuroendocrine carcinoma (LGNET).

F. Meric-Bernstam, A. Phan, J. Mares, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

1132OEVEROLIMUS (EVE) FOR THE TREATMENT OF ADVANCED PANCREATIC NEUROENDOCRINE TUMORS (PNET): FINAL OVERALL SURVIVAL (OS) RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO (PBO)-CONTROLLED, MULTICENTER PHASE III TRIAL (RADIANT-3).

E. D. de Vries, E. Van Cutsem, T. Hobday, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Everolimus plus octreotide LAR versus placebo plus octreotide LAR in patients with advanced neuroendocrine tumors (NET): Updated safety and efficacy results from RADIANT-2.

S. Ricci, M. Pavel, R. Winkler, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Everolimus in patients with advanced pancreatic neuroendocrine tumors (pNET): Updated results of a randomized, double-blind, placebo-controlled, multicenter phase III trial (RADIANT-3).

E. Van Cutsem, T. Hobday, C. Lombard-Bohas, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

New drug development in digestive neuroendocrine tumors.

R. Salazar, J. Tabernero, L. Siu, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Pilot Study of Concurrent 5-Fluorouracil/Paclitaxel Plus Radiotherapy in Patients With Carcinoma of the Esophagus and Gastroesophageal Junction

J. Ajani, J. Roth, S. Swisher, 2001, American journal of clinical oncology.

A phase II randomized trial of induction chemotherapy versus no induction chemotherapy followed by preoperative chemoradiation in patients with esophageal cancer.

P. Thall, J. Ajani, J. Roth, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

LBA25 FRESCO-2: A global phase III multiregional clinical trial (MRCT) evaluating the efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer

R. García-Carbonero, T. Yoshino, S. Lonardi, 2022, Annals of Oncology.

A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma

A. B. Benson, J. Ajani, A. Benson, 2008, Cancer Chemotherapy and Pharmacology.

A phase II trial of imatinib in patients with advanced carcinoid tumor.

L. Ellis, S. Curley, J. Ajani, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of liver tumor burden on therapeutic effect of 177Lu-dotatate treatment in NETTER-1 study.

E. Mittra, E. Krenning, T. Hobday, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Everolimus plus octreotide LAR (E+O) versus placebo plus octreotide LAR (P+O) in patients with advanced neuroendocrine tumors (NET): Updated results of a randomized, double-blind, placebo-controlled, multicenter phase III trial (RADIANT-2).

J. Hainsworth, E. Baudin, M. Pavel, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CT perfusion in normal liver and liver metastases from neuroendocrine tumors treated with targeted antivascular agents

A. Chandler, C. Ng, Payel Ghosh, 2018, Abdominal Radiology.

Pre-existing Symptoms and Healthcare Utilization Prior to Diagnosis of Neuroendocrine Tumors: A SEER-Medicare Database Study

A. Dasari, D. Halperin, J. Yao, 2018, Scientific Reports.

J. Hainsworth, E. Baudin, M. Pavel, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

R. Salazar, R. Riechelmann, E. Van Cutsem, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Preoperative therapy for local-regional gastric cancer: rationale and review of trials.

J. Ajani, J. Yao, 2000, Gan to kagaku ryoho. Cancer & chemotherapy.

Randomized, open-label, perioperative phase II study evaluating nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC.

J. Blando, J. Allison, R. Wolff, 2019, Annals of Oncology.

Phase ii trial of bevacizumab and erlotinib as a second-line therapy for advanced hepatocellular carcinoma

Manal M. Hassan, R. Wolff, Lianchun Xiao, 2016 .

Rapid decrease in blood flow (BF), blood volume (BV), and vascular permeability (PS) in carcinoid patients treated with bevacizumab.

J. Ajani, S. Faria, J. Abbruzzese, 2004, Journal of Clinical Oncology.

everolimus for the treatment of advanced gastrointestinal or lung nonfunctional neuroendocrine tumors in east asian patients: a subgroup analysis of the raDianT-4 study

Tetsuhide Ito, Y. Shimada, V. Sriuranpong, 2019 .

everolimus for the treatment of advanced gastrointestinal or lung nonfunctional neuroendocrine tumors in east asian patients: a subgroup analysis of the raDianT-4 study

Tetsuhide Ito, Y. Shimada, V. Sriuranpong, 2019 .

Effect of everolimus plus octreotide LAR treatment on chromogranin A and 5-hydroxyindoleacetic acid levels in patients with advanced neuroendocrine tumors: Phase III RADIANT-2 study results.

E. Baudin, Z. Tsuchihashi, G. Kaltsas, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical and Prognostic Biomarker Value of Blood-Circulating Inflammatory Cytokines in Hepatocellular Carcinoma

Manal M. Hassan, H. T. Tran Cao, Lianchun Xiao, 2023, Oncology.